Photodegradation of sparfloxacin and isolation of its degradation products by preparative HPLC

Revista de Ciencias Farmaceuticas Basica e Aplicada

Volumn 26, Issue 1, 2005, Pages 47-54

  Salgado, H R N ^a   Moreno, P R H ^b   Braga, A L ^c   Schapoval, E E S ^d  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Degradation products; Fluoroquinolone; Photodegradation; Quality control; Sparfloxacin; Stability

Indexed keywords

DRUG METABOLITE; METHANOL; SPARFLOXACIN; SPARFLOXACIN PDP1; SPARFLOXACIN PDP2; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG ISOLATION; DRUG MECHANISM; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROMETRY; MASS SPECTROMETRY; NONHUMAN; PHOTODEGRADATION; PROTON NUCLEAR MAGNETIC RESONANCE; ROOM TEMPERATURE; ULTRAVIOLET RADIATION;

EID: 33745648363     PISSN: 18084532     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. nd.ed. New York, Marcel Dekker, 1995.
2. Chao JB, Tong HB, Huang SP, Liu DS. Preparation and study on the solid inclusion complex of sparfloxacin with β-cyclodextrin. Spectrochim Acta Part A 2004;60:161-166.
3. Engler M, Rüsing G, Sörgel F, Holzgrabe U. Defluorinated sparfloxacin as a new photoproduct identified by liquid chromatography coupled with UV detection and tandem mass spectrometry. Antimicrob Agents Chemother 1998;42:1151-1159.
4. Ferguson J, McEwen J, Gohler K, Mignot A, Watson D. Phototoxic potential of gatifloxacin, a new fluoroquinolone antimicrobial. Drugs 1999;58:397-399.
5. Gau W, Kurz J, Petersen U, Ploschke HJ, Wuensche C. Isolation and structural elucidation of urinary metabolites of ciprofloxacin. Arzneimittel Forschung Drug Res 1986;36:1545-1549.
6. Goa KL, Bryson HM, Markham A. Sparfloxacin: a review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 1997;53:700-725.
7. Görög S. Identification and determination of impurities in drugs. Progress in Pharmaceutical and Biomedical Analysis, 2000. v.4. 772 p.
8. Hogerzeil HV, Battersby A, Srdanovic V, Stjernstrom NE. Stability of essential drugs during shipment to the tropics. Brit Med J 1992;304:210-212.
9. ICH-Harmonised Tripartity Guideline. International Conference on Harmonisation OF Technical Requirements for Registration of Pharmaceuticals for Human Use. Stability Testing: Photostability Testing of New Drug Substances and Products. Geneva: IFPMA, 1996, p. 1-10.
10. Koga H, Itoh A, Murayama S, Suzue S, Irikura T. Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alky 1-1,4-dihidro-4-oxoquinoline-3-carboxylic acids. J Med Chem 1980;23:1358-1363.
11. Kommanaboyina B, Rhodes CT. Trends in stability testing, with emphasis on stability during distribution and storage. Drug Dev Ind Pharm 1999;25:857-868.
12. Macías-Sanchez B, Cabarga MM, Navarro AS, Hurlé ADG. A physico-chemical study of the interaction of ciprofloxacin and ofloxacin with polyvalent cations, Int J Pharm 1994;106:229-235.
13. Marona HRN, Schapoval EES. Desarrollo de análisis microbiológico para la determinación de esparfloxacino en polvo y en comprimidos de 200 mg. Inf Tecnol 1998;9:251-254.
14. Marona HRN, Zuanazzi JAS, Schapoval EES. Determination of sparfloxacin and its degradation products by HPLC. J Antimicrob Chemother 1999;44:301-302.
15. Marona HRN, Schapoval EES. A high-performance liquid chromatographic assay of sparfloxacin. J Pharm Biomed Anal 1999;20:413-417.
16. Marona HRN, Schapoval EES. Spectrophotometric determination of sparfloxacin in tablets. J Antimicrob Chemother 1999;44:136-137.
17. Marona HRN, Schapoval EES. Analysis of sparfloxacin and its degradation products by bioassay. Acta Pharm Turcica 2001;43:7-9.
18. Marona HRN, Schapoval EES. Spectrophotometric determination of sparfloxacin in pharmaceutical formulations using bromothymol blue. J Pharm Biomed Anal 2001;26:501-504.
19. Marona HRN, Schapoval EES. Development and validation of a nonaqueous titration with perchloric acid to determine sparfloxacin in tablets. Eur J Pharm Biopharm 2001;52:227-229.
20. Marona HRN, Schapoval EES, Nardi NB. Análise citotóxica de esparfloxacino e seus proutos de degradação em células mononucleares humanas. Rev Ciênc Farm 2002;23:227-238.
21. Matthews BR. Regulatory aspects of stability testing in Europe. Drug Dev Ind Pharm 1999;25:831-856.
22. Miyamoto T, Matsumoto JI, Chiba K, Egawa H, Shibamori K, Minamida A, Nishimura Y, Okada H, Kataoka M, Fujita M, Hirose T, Nakano J. Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. J Med Chem 1990;33:1645-1656.
23. Phillips G, Johnson BE, Ferguson J. The loss of antibiotic activity of ciprofloxacin by photodegradation. J Antimicrob Chemother 1990;26:783-789.
24. Shimada J, Nogita T, Ishibashi Y. Clinical pharmacokinetics of sparfloxacin. Clin Pharmacok 1993;25:358-369.
25. Singh S, Bakshi M. Stress test to determine inherent stability of drugs. Pharm Technol 2000; 4:1-14.
26. Sparfloxacin Spara™ Zagam™. Drugs Fut 1999;24:581.
27. Sparfloxacin: focus on clinical performance. J Antimicrob Chemother 1996;37. (Whole issue).
28. Steele G. Preformulation predictions from small amounts of compound as an aid to candidate drug selection. In: Gibson M. Pharmaceutical Preformulation and Formulation. Boca Raton: Interpharm/CRC, 2004. Cap. 3, p.21-95.
29. Sunderland J, Tobin CM, White LO, MacGowan AP, Hedges AJ. Ofloxacin photodegradation products possess antimicrobial activity. Drugs 1999;58:171-172.
30. Thoma K, Kübier N. Untersuchungen zur Photostabilität von Gyrazehemmern. Pharmazie 1997;52:519-529.
31. Tobin CM, Sunderland J, MacGowan AP, Hedges AJ, White LO. Antimicrobial activity of moxifloxacin and levofloxacin photodegradation products. Drugs 1999;58:144-145.
32. Tønneson HH. Photochemical degradation of components in drug formulations. Part 1: An approach to the standardization of degradation studies. Pharmazie 1991;46:263-265.
33. 2. Brit J Dennatol 1999;140:784-787.
34. Yoshida Y, Sato E, Moroi R. Photodegradation products of levofloxacin in aqueous solution. Arzneimittel Forschung Drug Res 1993;43:601-606.